eFT508, a potent and highly selective inhibitor of MNK1 and MNK2, is an activator of anti-tumor immune response

被引：0
|
作者：
Webster, Kevin [1 ]
Sharma, Rajesh [1 ]
Goel, Vikas [1 ]
Stumpf, Craig [1 ]
Stauton, Jocelyn [1 ]
Thompson, Peggy [1 ]
Chiang, Gary [1 ]
Xu, Yichen [2 ]
Jin, Hyun Yong [2 ]
Ruggero, Davide [2 ]
机构：
[1] eFFECTOR Therapeut, San Diego, CA USA
[2] Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2017年 / 5卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P368
引用
收藏
页数：2
相关论文
共 50 条
  • [41] EVT-701 is a novel selective and safe mitochondrial complex 1 inhibitor with potent anti-tumor activity in models of solid cancers
    Luna Yolba, Raquel
    Visentin, Virgile
    Herve, Caroline
    Chiche, Johanna
    Ricci, Jean-Ehrland
    Meneyrol, Jerome
    Paillasse, Michael R.
    Alet, Nathalie
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2021, 9 (05):
  • [42] A highly potent and selective inhibitor Roxyl-WL targeting IDO1 promotes immune response against melanoma
    Xu, Guangwei
    Wang, Tianqi
    Li, Yongtao
    Huang, Zhi
    Wang, Xin
    Zheng, Jianyu
    Yang, Shengyong
    Fan, Yan
    Xiang, Rong
    JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2018, 33 (01) : 1089 - 1094
  • [43] Bcl-2 Inhibitor Combined with Radiotherapy and Anti-Tumor Immune Response through Inducing Immunogenic Cell Death
    Ma, M.
    Yuan, J.
    Zhang, Z.
    Chen, D.
    Yu, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : S215 - S215
  • [44] Discovery of highly potent, selective, and orally bioavailable IKZF2 degrader and its anti-tumor activity in syngeneic mouse models
    Park, Seulki
    Moon, Jeong Hee
    Lee, Gaseul
    Kim, Hyun Jin
    Kim, Jeong-Hoon
    Hwang, Jong Yeon
    CANCER RESEARCH, 2024, 84 (06)
  • [45] Potent anti-tumor activity correlated with inhibition of DNA damage response genes with highly selective and orally bioavailable CDK12 covalent inhibitors
    Poddutoori, R.
    Rajagopalan, S.
    Mukherjee, S.
    Marappan, S.
    Samiulla, D.
    Nayak, S.
    Sivakumar, S.
    Ravindra, M.
    Gore, S.
    Dhudashiya, A.
    Charamanna, K.
    Daginakatte, G.
    Chelur, S.
    Ramachandra, M.
    Samajdar, S.
    EUROPEAN JOURNAL OF CANCER, 2018, 103 : E94 - E95
  • [46] FCN-338, a novel and selective Bcl-2 inhibitor, exhibits potent anti-tumor activity in B-cell lymphoma
    Lin, Shu
    Zhao, Xingdong
    Liu, Hongbin
    Zhang, Huajie
    Chen, Zhifang
    Jiang, Lihua
    Liu, Yanxin
    Lin, Min
    Rong, Yue
    Tan, Rui
    Zhou, Zuwen
    Zou, Zongyao
    Gao, Yuwei
    Wang, Weibo
    CANCER RESEARCH, 2019, 79 (13)
  • [47] Fasnall, a Selective FASN Inhibitor, Shows Potent Anti-tumor Activity in the MMTV-Neu Model of HER2+ Breast Cancer
    Alwarawrah, Yazan
    Hughes, Philip
    Loiselle, David
    Carlson, David A.
    Darr, David B.
    Jordan, Jamie L.
    Xiong, Jessie
    Hunter, Lucas M.
    Dubois, Laura G.
    Thompson, J. Will
    Kulkarni, Manjusha M.
    Ratcliff, Annette N.
    Kwiek, Jesse J.
    Haystead, Timothy A. J.
    CELL CHEMICAL BIOLOGY, 2016, 23 (06): : 678 - 688
  • [48] INK128, a potent and selective TORC1/2 inhibitor, demonstrates anti-tumor activity in preclinical models of renal cell carcinoma by a distinct mechanism
    Liu, Y.
    Jessen, K.
    Wang, S.
    Kessler, L.
    Li, L.
    Darjania, L.
    Martin, M.
    Ren, P.
    Klein, P.
    Rommel, C.
    EJC SUPPLEMENTS, 2010, 8 (07): : 154 - 155
  • [49] A HIGHLY SELECTIVE AND POTENT HPK1 INHIBITOR ENHANCES IMMUNE CELL ACTIVATION AND INDUCES ROBUST TUMOR GROWTH INHIBITION IN A MURINE SYNGENEIC TUMOR MODEL
    Ciccone, David
    Lazari, Vad
    Linney, Ian
    Briggs, Michael
    Carreiro, Samantha
    McElwee, Joshua
    Waddell, Ian
    Hill, Chris
    Loh, Christine
    Tummino, Peter
    Collis, Alan
    Kaila, Neelu
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A411 - A411
  • [50] A highly selective and potent HPK1 inhibitor enhances immune cell activation and induces robust tumor growth inhibition in a murine syngeneic tumor model
    Ciccone, D.
    Lazari, V.
    Linney, I.
    Briggs, M.
    Carreiro, S.
    Waddell, I.
    Hill, C.
    Loh, C.
    Tummino, P.
    Collis, A.
    Kaila, N.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S20 - S20
12345